Catalyst Biosciences, Inc. (NASDAQ:CBIO) Logo

Analysts expect Catalyst Biosciences, Inc. (NASDAQ:CBIO) to report $-1.20 EPS on August, 1.They anticipate $0.66 EPS change or 122.22 % from last quarter’s $-0.54 EPS. After having $-1.26 EPS previously, Catalyst Biosciences, Inc.’s analysts see -4.76 % EPS growth. The stock increased 0.24% or $0.02 during the last trading session, reaching $8.45. About 74,785 shares traded. Catalyst Biosciences, Inc. (NASDAQ:CBIO) has declined 67.54% since July 19, 2018 and is downtrending. It has underperformed by 71.97% the S&P500.

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. The company has market cap of $101.23 million. The Company’s product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors. It currently has negative earnings. The firm also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration.

More notable recent Catalyst Biosciences, Inc. (NASDAQ:CBIO) news were published by: which released: “A Look At Benzinga Pro’s Most-Searched Tickers For July 8, 2019 – Benzinga” on July 08, 2019, also with their article: “Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B – GlobeNewswire” published on April 02, 2019, published: “Catalyst Biosciences Hosts Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs – GlobeNewswire” on December 18, 2018. More interesting news about Catalyst Biosciences, Inc. (NASDAQ:CBIO) were released by: and their article: “Catalyst Biosciences Announces Presentation at the 60th American Society of Hematology Annual Meeting & Exposition – GlobeNewswire” published on November 02, 2018 as well as‘s news article titled: “If You Had Bought Catalyst Biosciences (NASDAQ:CBIO) Stock Three Years Ago, You’d Be Sitting On A 68% Loss, Today – Yahoo Finance” with publication date: July 02, 2019.

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *